See more : Global-e Online Ltd. (GLBE) Income Statement Analysis – Financial Results
Complete financial analysis of MYND Life Sciences Inc. (MYNDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MYND Life Sciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Heiwa Paper Co.,Ltd. (9929.T) Income Statement Analysis – Financial Results
- Info Edge (India) Limited (NAUKRI.BO) Income Statement Analysis – Financial Results
- Paradigm Biopharmaceuticals Limited (PBIGF) Income Statement Analysis – Financial Results
- Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. (300313.SZ) Income Statement Analysis – Financial Results
- Amadeus FiRe AG (AAD.DE) Income Statement Analysis – Financial Results
MYND Life Sciences Inc. (MYNDF)
About MYND Life Sciences Inc.
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. The company is headquartered in Kelowna, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 92.99K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 332.99K | 180.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -240.00K | -180.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -258.09% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 282.28K | 1.18M | 1.08M | 0.00 | 0.00 |
| General & Administrative | 823.05K | 1.38M | 2.72M | 6.68K | 2.54K |
| Selling & Marketing | 362.07K | 136.16K | 409.46K | 49.79 | 0.00 |
| SG&A | 1.19M | 1.51M | 3.13M | 56.47K | 2.54K |
| Other Expenses | 121.38K | 14.38K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.59M | 2.88M | 4.29M | 56.47K | 2.54K |
| Cost & Expenses | 1.83M | 3.06M | 4.29M | 56.47K | 2.54K |
| Interest Income | 0.00 | 662.91 | 134.88 | 0.00 | 0.00 |
| Interest Expense | 731.76K | 662.91K | 134.88K | 0.00 | 0.00 |
| Depreciation & Amortization | 20.99K | 59.83K | 86.12K | 56.47K | 2.54K |
| EBITDA | -1.83M | -2.99M | -4.28M | 0.00 | 0.00 |
| EBITDA Ratio | -1,962.79% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.83M | -3.73M | -4.29M | -56.47K | -2.54K |
| Operating Income Ratio | -1,966.62% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 310.90K | -633.98K | -243.93K | 0.00 | 0.00 |
| Income Before Tax | -1.52M | -3.70M | -4.54M | -56.47K | -2.54K |
| Income Before Tax Ratio | -1,632.28% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -129.95K | -168.31K | 0.00 | 0.00 |
| Net Income | -1.52M | -3.57M | -4.37M | -56.47K | -2.54K |
| Net Income Ratio | -1,632.28% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -0.08 | -0.10 | 0.00 | 0.00 |
| EPS Diluted | -0.03 | -0.08 | -0.10 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 47.27M | 46.68M | 44.96M | 28.23M | 1.71M |
| Weighted Avg Shares Out (Dil) | 47.27M | 46.68M | 44.96M | 28.23M | 1.71M |
MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a leader in mental health diagnostics and treatments, today announced two significant strategic decisions aimed at strengthening the company's financial...
MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced...
MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") The Company is pleased to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board.
MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a pioneering biopharmaceutical research and development company committed to advancing treatments for patients coping with chronic and acute neurological and inflammatory diseases, is...
Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), We are delighted to announce the appointment of Mynd Life Sciences current CEO and Director, the Hon. Dr. Lyle Oberg, E.C.A.
MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.
Potential merger to create new industry leader. Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a pioneering biopharmaceutical research and development company dedicated to revolutionizing treatments for patients...
MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures
MYND Life Sciences was formed to commercialize proprietary biomarker diagnostic tests and novel therapeutics for patients suffering from MDD, TRD and other neuro-inflammatory disorders Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB:...
Source: https://incomestatements.info
Category: Stock Reports